Mitchell R. Smith
YOU?
Author Swipe
View article: Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide
Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide Open
Background The prognostic utility of positron emission tomography/computer tomography (PET/CT) scan and bone marrow biopsy (BMB) as response assessments in mantle cell lymphoma (MCL) is incompletely explored. We sought to: 1) interrogate t…
View article: Conformal Coating Testing in Various Test Environments
Conformal Coating Testing in Various Test Environments Open
Conformal coatings have traditionally been tested by determining the mean time to failure of conformally coated hardware exposed to corrosive test environments. This test approach has serious shortcomings: The test temperatures are most of…
View article: Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy Open
KEYWORDS: PI3K inhibitorsNon-Hodgkin lymphomaFDA approvaldrug developmentClinical trial endpointsrelapsed/refractoryindolent B cell lymphoma
View article: Data from Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells
Data from Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells Open
MTOR complex-1(mTORC1) activation occurs frequently in cancers, yet clinical efficacy of rapalogs is limited because of the associated activation of upstream survival pathways. An alternative approach is to inhibit downstream of mTORC1; th…
View article: Data Supplement from Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells
Data Supplement from Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells Open
Supplementary Legend for Figure S1. P70S6k knockdown does not impact on cell death in Nalm-6 cells. (a) Western blot analysis of p70S6K knockdown in Nalm-6 cells. β-actin was used as a loading control. (b). Cell death analysis in siControl…
View article: Data from Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells
Data from Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells Open
MTOR complex-1(mTORC1) activation occurs frequently in cancers, yet clinical efficacy of rapalogs is limited because of the associated activation of upstream survival pathways. An alternative approach is to inhibit downstream of mTORC1; th…
View article: Supplementary Table S2 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Supplementary Table S2 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Open
Mass spectrometric analysis of proteins that bound to B-CCF642 in MM1.S cells
View article: Supplementary Figure S1 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Supplementary Figure S1 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Open
Structure, H-NMR and HRMS of CCF642, B-CCF642 and CCF642-COOH
View article: Data from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Data from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Open
Multiple myeloma cells secrete more disulfide bond–rich proteins than any other mammalian cell. Thus, inhibition of protein disulfide isomerases (PDI) required for protein folding in the endoplasmic reticulum (ER) should increase ER stress…
View article: Data from Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Data from Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma Open
Purpose: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/r…
View article: Supplementary Figure S1 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Supplementary Figure S1 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Open
Structure, H-NMR and HRMS of CCF642, B-CCF642 and CCF642-COOH
View article: Data from Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Data from Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma Open
Purpose: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/r…
View article: Supplementary Table S1 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Supplementary Table S1 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Open
Small molecule screening data
View article: Supplementary Figure Legends from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Supplementary Figure Legends from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Open
Legends to Supplementary Figures S1-4
View article: Data from Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Data from Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma Open
Purpose: AME-133v is a humanized monoclonal antibody engineered to have increased affinity to CD20 and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) better than rituximab. Safety, pharmacokinetics, and efficacy were assessed…
View article: Supplementary Tables 1-4 from Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Supplementary Tables 1-4 from Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma Open
PDF file - 62K
View article: Supplementary Figure Legends from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Supplementary Figure Legends from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Open
Legends to Supplementary Figures S1-4
View article: Supplementary Figure 1 from Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Supplementary Figure 1 from Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma Open
Representative images (20 x magnification) of formalin-fixed paraffin-embedded clots prepared from bone marrow aspirates.
View article: Supplementary Table S2 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Supplementary Table S2 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Open
Mass spectrometric analysis of proteins that bound to B-CCF642 in MM1.S cells
View article: Data from Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Data from Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma Open
Purpose: AME-133v is a humanized monoclonal antibody engineered to have increased affinity to CD20 and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) better than rituximab. Safety, pharmacokinetics, and efficacy were assessed…
View article: Data from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Data from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Open
Multiple myeloma cells secrete more disulfide bond–rich proteins than any other mammalian cell. Thus, inhibition of protein disulfide isomerases (PDI) required for protein folding in the endoplasmic reticulum (ER) should increase ER stress…
View article: Supplementary Table S1 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Supplementary Table S1 from Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Open
Small molecule screening data
View article: Supplementary Figure Legends 1-2 from Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity
Supplementary Figure Legends 1-2 from Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity Open
PDF file - 65K
View article: Supplementary Figure 2 from Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity
Supplementary Figure 2 from Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity Open
PDF file - 426K, Percent of T-cells